Harrow News

B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $29

B.Riley Financial analyst Mayank Mamtani maintains $Harrow(HROW.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 25.4% and a

moomoo NewsJun 6 14:32 ET

Express News | Corrected-Melt Pharmaceuticals (Not 'harrow Inc'): Topline Readout Expected in Q4 2024

ReutersJun 6 08:48 ET

Express News | Harrow Inc: Topline Readout Expected in Q4 2024

ReutersJun 6 08:00 ET

Express News | Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, Melt-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

ReutersJun 6 08:00 ET

Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating

Craig-Hallum analyst Chase Knickerbocker maintains $Harrow(HROW.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.5% and a total average return of 2.7% over the p

moomoo NewsJun 5 09:33 ET

Harrow's VEVYE Shows Results for Dry Eye Disease in ESSENCE-2 Study

Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‐2 open-label extension (OLE) clinical study for VEVYE (cyclosporine ophth

BenzingaJun 5 07:10 ET

Express News | Harrow Announces 52-Week Data From Vevye® Essence-2 Open-Label Extension Study

ReutersJun 5 07:00 ET

Harrow Is Maintained at Buy by Lake Street

Harrow Is Maintained at Buy by Lake Street

Dow JonesJun 3 11:11 ET

Express News | Lake Street Maintains Buy on Harrow, Raises Price Target to $25

BenzingaJun 3 11:01 ET

The AISL Harrow Scholarships 2024/26: Doubling Success, as Awardees Soar to New Heights

Yahoo FinanceMay 27 02:00 ET

Harrow (NASDAQ:HROW) Stock Surges on Successful Product Launch

TipRanksMay 23 06:29 ET

Harrow Price Target Raised to $26.00/Share From $24.00 by Craig-Hallum

Harrow Price Target Raised to $26.00/Share From $24.00 by Craig-Hallum

Dow JonesMay 15 14:02 ET

Harrow Is Maintained at Buy by Craig-Hallum

Harrow Is Maintained at Buy by Craig-Hallum

Dow JonesMay 15 14:02 ET

Express News | B. Riley Securities Reiterates Buy on Harrow, Raises Price Target to $29

BenzingaMay 15 10:11 ET

Harrow Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 75.76% B. Riley Securities $26 → $29 Reiterates Buy → Buy 04/11/2024 45.45% Craig-Hallum → $24

BenzingaMay 15 10:09 ET

Express News | Harrow, Inc. : Craig-Hallum Raises Target Price to $26 From $24

ReutersMay 15 07:15 ET

Harrow to Present at Two Investor Conferences in May

NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor

BusinesswireMay 15 07:00 ET

Harrow Inc (HROW) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic Advances

Yahoo FinanceMay 15 03:00 ET

Express News | Harrow Inc : B. Riley Raises Target Price to $29 From $26

ReutersMay 15 00:51 ET

Earnings Call Summary | Harrow(HROW.US) Q1 2024 Earnings Conference

The following is a summary of the Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript:Financial Performance:Harrow Inc. reported a rise of 33% in revenues for Q1 2024 compared to Q1 2023.Increased it

moomoo AIMay 14 16:31 ET · Conference Call